CVC Completes Therakos Acquisition from Mallinckrodt

CVC Capital Partners, a leading global private markets manager, has completed the acquisition of Therakos, a business previously owned by Mallinckrodt plc, the global specialty pharmaceutical company. This acquisition was supported by CVC Capital Partners Fund IX and aims to leverage CVC's resources and expertise to boost Therakos' offerings, which center around Extracorporeal Photopheresis (ECP) systems for autologous immunomodulatory therapy. Therakos has achieved approvals across multiple regions including the U.S., Canada, Europe, and others, marking it as a leader in the field. The business will be led by Co-CEOs Michael Rechtiene and Sandra Thompson, who are returning to their roles. They aim to further drive innovation in the ECP therapy sector under this new ownership. CVC is optimistic about the potential for expanding Therakos' reach and impact. Supporting this acquisition, UBS served as the financial advisor, Freshfields Bruckhaus Deringer as the legal counsel, with PWC and Candesic providing financial and commercial advice, respectively.